CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on January 13, 2020
Heat Biologics, Inc.
627 Davis Drive, Suite 400
Morrisville, North Carolina 27560
January 13, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Paul Fischer
Re: Heat Biologics, Inc.
Registration Statement on Form S-1
File No. 333-234105
Dear Mr. Fischer:
Heat Biologics, Inc. (the Company) hereby requests that the effective date of the Companys Registration Statement on Form S-1, as amended (File No. 333-234105), be accelerated by the U.S. Securities and Exchange Commission to Tuesday, January 14, 2020 at 5:00 pm, Eastern Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes its legal counsel, Leslie Marlow and Patrick Egan of Gracin & Marlow, LLP, to modify or withdraw (orally or in writing) this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|
Very truly yours, |
|
|
|
|
|
Heat Biologics, Inc. |
|
|
|
|
|
|
|
|
By: |
/s/ Jeffrey Wolf |
|
|
Name: Jeffrey Wolf |
|
|
Title: Chief Executive Officer |
cc: Leslie Marlow, Gracin & Marlow, LLP
Patrick Egan, Gracin & Marlow, LLP